Thyroid medicine recalled nationwide: FDA

Major Pharmaceuticals has issued a nationwide recall for specific batches of Levothyroxine Sodium tablets. Federal regulators at the Food and Drug Administration classify this as a Class II recall. This means the medication is subpotent and may not provide the full therapeutic effect required to treat conditions such as hypothyroidism and goiter.

The recall process began on July 13 and affects several dosage strengths, including 25, 50, 75, 88, 112, and 150 microgram tablets. These medications were distributed in 10-count blister packs, either sold individually or grouped into cartons of 100 tablets. The impacted lots carry expiration dates ranging from July 2026 through January 2027.

While Major Pharmaceuticals handled the primary distribution, the FDA notes that Cardinal Health also distributed some of the affected supply. Patients who use this medication should inspect their pill packaging immediately to identify if their product is part of the recalled group. Contact your pharmacy or healthcare provider if you have questions regarding your specific prescription or to arrange for a replacement.

The agency notes that subpotent thyroid medication can lead to inadequate treatment of thyroid conditions. While the risk of temporary adverse health consequences is present, the FDA is taking this action to ensure consumer safety and product efficacy. Always check with a pharmacist before stopping any prescribed medication, and keep updated on official FDA announcements regarding this recall.